can and does impact treatment and subsequent patient outcomes as pain medicine providers.
We are at the forefront of change in the cannabis industry and with that comes uncertainty in not only treatment modalities but also safety and long-term side effects. The article mentions, ''And while there are concerns over the relatively unknown long-term consequence of cannabis use, its use in medical management is surely to continue.'' Patient's use of CBD oil and other cannabis-related products continue to rise and with that comes the subsequent gold rush of people trying to make money of the naivety of patients looking for something to treat their conditions. This leads to many products being put on the market that are either mislabeled, contain no CBD, or even worse contain unintended dangerous hormones due to their production in China. This is well documented in the JAMA article in 2017 titled: ''Labeling Accuracy of Cannabidiol Extracts Sold Online'' [2] .
This results in the patients shouldering the burden of sorting through the hundreds of companies to find a legitimate or trustworthy CBD oil. As referred to in the article, CBD can elevate liver enzymes and is metabolized through the similar liver pathways of many common prescription medications, which can cause unintended side effects of other medications they may be taking on a daily basis. Chronic pain patients should not be tasked with having to distinguish between legitimate and potentially harmful CBD products.
If we want to make cannabis and CBD into a legitimate medicinal treatment, there must be more regulations on CBD oil production and accurate labeling. Patients will continue to seek CBD oil as an additional option to treat their chronic pain as it gains popularity, so it is our duty as providers to protect them and ensure they have safe options of this new medication to choose from.
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